Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation – QNT Press Release


SHANGHAI, Aug. 27, 2022 /PRNewswire/ — Recently, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (Sanyou) and Shanghai KangaBio Co., Ltd. (KangaBio) have reached an antibody drug licensing agreement, regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an exclusive license to exploit the antibody for research , development, manufacturing and commercialization of immunotherapy products. KangaBio, as a rising star biotechnology company, is committed to developing innovative prodrugs and providing innovative medicine to address unmet clinical needs. While Sanyou is a biological high-tech company focusing on innovative antibody drugs R&D services. Based on the two companies’ respective strengths and industry resources, Sanyou and KangaBio will work together to contribute to the development of innovative prodrugs for immunotherapy.

Previously, KangaBio and Sanyou reached a collaboration agreement on two monoclonal antibody drugs developed by Sanyou and signed high-level term sheet. In …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center